Pharmaceutical Preparations · DE · CIK 1690585
Developing best-in-class therapies for severe autoimmune diseases using novel antibody and fusion protein candidates
Comparable business profile · signals at a glance
In the 90 days to Mar 24, 2026: 4 sold $18.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 24, 2026 | Soteropoulos PaulaDirector | Sell | 27,594 | $78.05 | $2.2M |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 65,517 | $81.74 | $5.4M |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 43,505 | $80.69 | $3.5M |
| Mar 12, 2026 | Randhawa SimratEVP, Head of R&D | Sell | 33,830 | $81.48 | $2.8M |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 23,465 | $81.75 | $1.9M |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 15,852 | $80.71 | $1.3M |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 12,796 | $82.60 | $1.1M |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 3,865 | $82.66 | $319K |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 900 | $85.53 | $77K |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 300 | $85.53 | $26K |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 200 | $83.38 | $17K |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 200 | $83.38 | $17K |
| Dec 4, 2025 | Savitz RyanCFO & CBO | Sell | 20,000 | $45.18 | $904K |
| Nov 14, 2025 | Randhawa SimratEVP, Head of R&D | Sell | 109,031 | $38.14 | $4.2M |
| Nov 13, 2025 | Randhawa SimratEVP, Head of R&D | Sell | 42,765 | $37.04 | $1.6M |
| Nov 13, 2025 | Randhawa SimratEVP, Head of R&D | Sell | 26,166 | $35.80 | $937K |
| Nov 13, 2025 | Randhawa SimratEVP, Head of R&D | Sell | 18,576 | $37.72 | $701K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Coverage (30d): 1 reputable article · skews – neutral.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗